PR Newswire All News ReleasesQwen · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 15:24:00·⟳ 抓取 15:24:32 +32s·⚡ 决策 08-31 20:31:58 +5h07m·57.0 天前
律所SBS Law发布Capricor Therapeutics（CAPR）证券欺诈集体诉讼首席原告征集广告
同一具体催化（SBS Law的CAPR证券诉讼征集稿）在2分钟前（07:26 UTC）已被处理并判定不做；同一诉讼的其它律所版本（DJS、Hagens Berman、Robbins Geller）在72小时内也均已处理。本条不含任何新增事实——无新FDA决定、无法院新裁定、无公司新披露、无新赔偿金额，仅为律所广告。底层负面催化（AdCom 9:3反对、PDUFA延期）早已公开定价，做空边际不足，做多无逻辑。
📄 原文PR Newswire All News Releases↗ 原文
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES,…
不做 Capricor Therapeutics（CAPR.US）
本条为律所证券诉讼征集广告，不含任何新增事实；同一具体催化（SBS Law版本）在2分钟前已被处理判定不做，同一诉讼的DJS、Hagens Berman、Robbins Geller版本也在72小时内处理完毕。底层负面（AdCom反对、PDUFA延期）已充分传播并定价，做空边际不足，做多无逻辑。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
本条是Schall, Brown & Schwartz律所通过PR Newswire发布的CAPR证券集体诉讼首席原告征集广告。核心指控（Deramiocel BLA统计分析计划变更、FDA未同意）和底层负面事件（2026年7月AdCom反对、8月PDUFA延期）均已在数周前公开并导致股价重定价。72小时内同一诉讼已有4条律所征集稿被处理并全部判定不做。本条无任何新增事实，不构成可交易催化。
🔎 新鲜度:最早出现 2026-07-27 · 扩散 high · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:无需先例：本条为无增量事实的律所广告，不进入交易评估
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 72 ms
{"result": "search_processed_events:agent query=`capr deramiocel bla class action | capricor therapeutics capr securities fraud lawsuit | capricor 证券欺诈集体诉讼`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.2/72 小时、1063 条本臂决策(完整)，返回 4 条候选。\n• 08-31 07:31 UTC(CST 15:31) [ticker] 不做 CAPR.US (news_center) — Capricor Therape
原文全文
展开原文 · 2,837 字
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor changed the statistical analysis plan used to analyze the clinical data related to Deramiocel despite the fact that the FDA had not agreed to changes from the pre-specified plan before the resubmission of its Biologics License Application ("BLA"). The Company faced a significant risk the FDA would not approve the BLA for Deramiocel based on a lack of sufficient evidence of effectiveness. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: December 17, 2025 to July 26, 2026
DEADLINE: September 28, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Capricor changed the statistical analysis plan used to analyze the clinical data related to Deramiocel despite the fact that the FDA had not agreed to changes from the pre-specified plan before the resubmission of its Biologics License Application ("BLA"). The Company faced a significant risk the FDA would not approve the BLA for Deramiocel based on a lack of sufficient evidence of effectiveness. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Capricor, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。